Disclosed positions
| X4 PHARMACEUTICALS INC | XFOR | COM NEW | $32,365,860 | 6,930,591 | SH | None |
| EMPERY DIGITAL INC | EMPD | COM NEW | $10,432,028 | 2,930,345 | SH | None |
| NERVGEN PHARMA CORP | NGEN | COM | $8,240,000 | 4,000,000 | SH | None |
| PRECISION BIOSCIENCES INC | DTIL | COM NEW | $6,100,091 | 776,093 | SH | None |
| CLENE INC | CLNN | COM NEW | $5,641,254 | 916,532 | SH | None |
| ANNOVIS BIO INC | ANVS | COM | $4,466,745 | 2,401,476 | SH | None |
| LANTERN PHARMA INC | LTRN | COM | $3,513,930 | 842,669 | SH | None |
| AMC ENTMT HLDGS INC | AMC | CL A NEW | $3,256,682 | 1,714,043 | SH | None |
| TENAYA THERAPEUTICS INC | TNYA | COM | $2,855,228 | 3,863,115 | SH | None |
| ONE AND ONE GREEN TECHNOLOGI | Unresolved | USD CL A ORD SHS | $1,538,646 | 761,706 | SH | None |
| CYNGN INC | CYN | COM | $1,288,612 | 927,059 | SH | None |
| VENU HLDG CORP | VENU | COM | $1,164,097 | 512,818 | SH | None |
| GREENLAND ENERGY CO | GLNDW | *W EXP 04/21/203 | $850,000 | 1,000,000 | SH | None |
| UR-ENERGY INC | URG | COM | $843,385 | 620,136 | SH | None |
| SATELLOS BIOSCIENCE INC | MSLE | COM | $832,703 | 107,100 | SH | None |
| JAGUAR URANIUM CORP | JAGU | CL A COM SHS | $814,125 | 487,500 | SH | None |
| CELLECTAR BIOSCIENCES INC | CLRB | COM NEW | $527,102 | 189,605 | SH | None |
| SCYNEXIS INC | SCYX | COM | $514,656 | 126,451 | SH | None |
| REIN THERAPEUTICS INC | RNTX | COM NEW | $385,667 | 370,834 | SH | None |
| BTC DIGITAL LTD | Unresolved | SHS NEW | $288,912 | 350,877 | SH | None |
| BRIACELL THERAPEUTICS CORP | BCTXL | *W EXP 01/15/203 | $267,000 | 300,000 | SH | None |
| MARIS TECH LTD | Unresolved | *W EXP 02/04/202 | $58,032 | 297,600 | SH | None |
| PARAZERO TECHNOLOGIES LTD | Unresolved | SHS | $55,338 | 113,771 | SH | None |
| DUKE ROBOTICS CORP | DUKRW | *W EXP 05/06/203 | $45,150 | 35,000 | SH | None |
| NUTRIBAND INC | NTRBW | *W EXP 99/99/999 | $40,218 | 40,218 | SH | None |
| RENATUS TACTICAL ACQUIS | Unresolved | *W EXP 05/15/203 | $38,000 | 50,000 | SH | None |
| SPECTRAL AI INC | MDAIW | *W EXP 09/11/202 | $18,501 | 33,336 | SH | None |
| NEXERA TECHNOLOGIES LTD | Unresolved | *W EXP 08/26/202 | $10,421 | 360,577 | SH | None |
| CEA INDUSTRIES INC | BNCWW | *W EXP 02/11/202 | $9,250 | 500,000 | SH | None |
| FGI INDUSTRIES LTD | Unresolved | *W EXP 99/99/999 | $7,973 | 83,928 | SH | None |
| NEUROSENSE THERAPEUTICS LTD | Unresolved | *W EXP 11/10/202 | $6,325 | 100,402 | SH | None |
| NEXGEL INC | NXGLW | *W EXP 12/27/202 | $3,474 | 90,000 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 8 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.